Interstitial lung disease
RecruitingSafety, Pharmacokinetics, and Exploratory Efficacy of BI 1015550 and Nerandomilast in Children and Adolescents Aged 2‑17 Years With Fibrosing Interstitial Lung Disease
Safety, Pharmacokinetics, and Exploratory Efficacy of BI 1015550 and Nerandomilast in Children and Adolescents Aged 2‑17 Years With Fibrosing Interstitial Lung Disease
- Disease:Interstitial lung disease
- Substances:Nerandomilast
Germany- Participants:0–17 years
- Substances:Nerandomilast
- Sponsor:Boehringer Ingelheim Espana S.A.












